Ionis Pharmaceuticals (ISI) Stock Forecast & Price Target

5 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ISI Analyst Ratings

Strong Buy

17 Buy

4 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Ionis

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ISI Stock 12 Month Forecast

Average Price Target

€74.82

▲(37.84% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Ionis Pharmaceuticals in the last 3 months. The average price target is €74.82 with a high forecast of €92.63 and a low forecast of €48.10. The average price target represents a 37.84% change from the last price of €54.28.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"38":"€38","93":"€93","51.75":"€51.8","65.5":"€65.5","79.25":"€79.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":92.63275632,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€92.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":74.81876472000002,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€74.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.09777732,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€48.10</span>\n  </div></div>","useHTML":true}}],"tickPositions":[38,51.75,65.5,79.25,93],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.52,43.60559664,47.69119328,51.77678992,55.862386560000004,59.947983199999996,64.03357984,68.11917648,72.20477312,76.29036976,80.3759664,84.46156303999999,88.54715968,{"y":92.63275632,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.52,42.23528959384616,44.95057918769231,47.66586878153847,50.38115837538462,53.09644796923078,55.81173756307693,58.52702715692309,61.24231675076925,63.9576063446154,66.67289593846155,69.38818553230772,72.10347512615387,{"y":74.81876472000002,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.52,40.17982902461539,40.83965804923077,41.499487073846154,42.15931609846154,42.81914512307692,43.47897414769231,44.13880317230769,44.79863219692308,45.458461221538464,46.11829024615385,46.77811927076923,47.437948295384615,{"y":48.09777732,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":55.26,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 68,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.86,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.96,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.32,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.04,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.8,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.58,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.58,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.62,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.7,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.85,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.36,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 70,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.52,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€92.63

Average Price Target€74.82

Lowest Price Target€48.10

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jason Gerberry

Bank of America Securities

€81.05

Buy

49.33%

Upside

Reiterated

10/09/26

Ionis Pharmaceuticals (IONS) Receives a Buy from Bank of America Securities

Mitchell Kapoor

H.C. Wainwright

€89.07

Buy

64.09%

Upside

Reiterated

10/08/26

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), United Therapeutics (NASDAQ: UTHR) and Ionis Pharmaceuticals (NASDAQ: IONS)

Luca Issi

RBC Capital

€75.71

Buy

39.48%

Upside

Reiterated

10/08/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Justin Kim

Oppenheimer

€75.71

Buy

39.48%

Upside

Reiterated

09/24/26

Oppenheimer Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

Gary Nachman

Canaccord Genuity

€75.71

Buy

39.48%

Upside

Reiterated

09/24/26

Canaccord Genuity Remains a Buy on Ionis Pharmaceuticals (IONS)

Yaron Werber

TD Cowen

€74.82

Buy

37.84%

Upside

Reiterated

09/23/26

Analysts Offer Insights on Healthcare Companies: Immunovant (NASDAQ: IMVT) and Ionis Pharmaceuticals (NASDAQ: IONS)

Joseph Stringer

Needham

€76.6

Buy

41.12%

Upside

Reiterated

09/23/26

Stringer Reiterates Buy on Ionis as Late-Stage Pipeline Delivers; Price Target Maintained at $86

David Lebowitz

BMO Capital

€48.1

Hold

-11.39%

Downside

Reiterated

09/23/26

Analysts Offer Insights on Healthcare Companies: NanoViricides (NYSE MKT: NNVC) and Ionis Pharmaceuticals (NASDAQ: IONS)

Myles Minter

William Blair

―

Buy

―

Reiterated

09/22/26

Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (NASDAQ: MAZE) and Ionis Pharmaceuticals (NASDAQ: IONS)

Jessica Fye

J.P. Morgan

€62.35

Buy

14.87%

Upside

Assigned

09/22/26

Ionis Pharmaceuticals price target lowered to $70 from $76 at JPMorganIonis Pharmaceuticals price target lowered to $70 from $76 at JPMorgan

Eliana Merle

Barclays

€75.71

Buy

39.48%

Upside

Reiterated

09/18/26

Analysts' Top Healthcare Picks: Ionis Pharmaceuticals (IONS), Healthequity (HQY)

Debjit Chattopadhyay

Guggenheim

€79.27→€71.26

Buy

31.27%

Upside

Reiterated

09/14/26

Guggenheim Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)

Salveen Richter

Goldman Sachs

€61.46→€49.88

Hold

-8.11%

Downside

Reiterated

09/14/26

Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (NASDAQ: SRRK), Axsome Therapeutics (NASDAQ: AXSM) and Ionis Pharmaceuticals (NASDAQ: IONS)

Michael Ulz

Morgan Stanley

€92.63

Buy

70.66%

Upside

Assigned

09/09/26

Ionis Pharmaceuticals (IONS) Gets a Buy from Morgan Stanley

Tiago Fauth

Raymond James

€77.49→€74.82

Buy

37.84%

Upside

Reiterated

09/08/26

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN), Ionis Pharmaceuticals (NASDAQ: IONS) and Brainsway (NASDAQ: BWAY)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jason Gerberry

Bank of America Securities

€81.05

Buy

49.33%

Upside

Reiterated

10/09/26

Ionis Pharmaceuticals (IONS) Receives a Buy from Bank of America Securities

Mitchell Kapoor

H.C. Wainwright

€89.07

Buy

64.09%

Upside

Reiterated

10/08/26

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), United Therapeutics (NASDAQ: UTHR) and Ionis Pharmaceuticals (NASDAQ: IONS)

Luca Issi

RBC Capital

€75.71

Buy

39.48%

Upside

Reiterated

10/08/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Justin Kim

Oppenheimer

€75.71

Buy

39.48%

Upside

Reiterated

09/24/26

Oppenheimer Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

Gary Nachman

Canaccord Genuity

€75.71

Buy

39.48%

Upside

Reiterated

09/24/26

Canaccord Genuity Remains a Buy on Ionis Pharmaceuticals (IONS)

Yaron Werber

TD Cowen

€74.82

Buy

37.84%

Upside

Reiterated

09/23/26

Analysts Offer Insights on Healthcare Companies: Immunovant (NASDAQ: IMVT) and Ionis Pharmaceuticals (NASDAQ: IONS)

Joseph Stringer

Needham

€76.6

Buy

41.12%

Upside

Reiterated

09/23/26

Stringer Reiterates Buy on Ionis as Late-Stage Pipeline Delivers; Price Target Maintained at $86

David Lebowitz

BMO Capital

€48.1

Hold

-11.39%

Downside

Reiterated

09/23/26

Analysts Offer Insights on Healthcare Companies: NanoViricides (NYSE MKT: NNVC) and Ionis Pharmaceuticals (NASDAQ: IONS)

Myles Minter

William Blair

―

Buy

―

Reiterated

09/22/26

Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (NASDAQ: MAZE) and Ionis Pharmaceuticals (NASDAQ: IONS)

Jessica Fye

J.P. Morgan

€62.35

Buy

14.87%

Upside

Assigned

09/22/26

Ionis Pharmaceuticals price target lowered to $70 from $76 at JPMorganIonis Pharmaceuticals price target lowered to $70 from $76 at JPMorgan

Eliana Merle

Barclays

€75.71

Buy

39.48%

Upside

Reiterated

09/18/26

Analysts' Top Healthcare Picks: Ionis Pharmaceuticals (IONS), Healthequity (HQY)

Debjit Chattopadhyay

Guggenheim

€79.27→€71.26

Buy

31.27%

Upside

Reiterated

09/14/26

Guggenheim Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)

Salveen Richter

Goldman Sachs

€61.46→€49.88

Hold

-8.11%

Downside

Reiterated

09/14/26

Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (NASDAQ: SRRK), Axsome Therapeutics (NASDAQ: AXSM) and Ionis Pharmaceuticals (NASDAQ: IONS)

Michael Ulz

Morgan Stanley

€92.63

Buy

70.66%

Upside

Assigned

09/09/26

Ionis Pharmaceuticals (IONS) Gets a Buy from Morgan Stanley

Tiago Fauth

Raymond James

€77.49→€74.82

Buy

37.84%

Upside

Reiterated

09/08/26

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN), Ionis Pharmaceuticals (NASDAQ: IONS) and Brainsway (NASDAQ: BWAY)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

IMUXImmunic

REPLReplimune Group

OVIDOvid Therapeutics

CELCCelcuity

ARDXArdelyx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ionis Pharmaceuticals

3 Months

Myles MinterWilliam Blair

Success Rate

12/22 ratings generated profit

Average Return

+6.66%

Copying Myles Minter's trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +6.66% per trade.

1 Year

Gary NachmanCanaccord Genuity

Success Rate

16/27 ratings generated profit

Average Return

+17.30%

Copying Gary Nachman's trades and holding each position for 1 Year would result in 59.26% of your transactions generating a profit, with an average return of +17.30% per trade.

2 Years

Yanan ZhuWells Fargo

Success Rate

22/29 ratings generated profit

Average Return

+21.64%

Copying Yanan Zhu's trades and holding each position for 2 Years would result in 75.86% of your transactions generating a profit, with an average return of +21.64% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ISI Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ISI has received 39 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. ISI average Analyst price target in the past 3 months is 74.82.

Each month's total comprises the sum of three months' worth of ratings.

ISI Financial Forecast

ISI Earnings Forecast

Next quarter’s earnings estimate for ISI is -€1.08 with a range of -€1.27 to -€0.86. The previous quarter’s EPS was -€0.62. ISI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ISI has Performed in-line its overall industry.

ISI Sales Forecast

Next quarter’s sales forecast for ISI is €163.45M with a range of €139.55M to €200.81M. The previous quarter’s sales results were €239.15M. ISI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ISI has Performed in-line its overall industry.

ISI Stock Forecast FAQ

What is DE:ISI’s average 12-month price target, according to analysts?

Based on analyst ratings, Ionis Pharmaceuticals’s 12-month average price target is 74.82.

What is DE:ISI’s upside potential, based on the analysts’ average price target?

Ionis Pharmaceuticals has 37.84% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Ionis Pharmaceuticals a Buy, Sell or Hold?

Ionis Pharmaceuticals has a consensus rating of Strong Buy, which is based on 17 buy ratings, 4 hold ratings and 0 sell ratings.

What is Ionis Pharmaceuticals’s share price target?

The average share price target for Ionis Pharmaceuticals is 74.82. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €92.63 ,and the lowest forecast is €48.10. The average share price target represents 37.84% Increase from the current price of €54.28.

What do analysts say about Ionis Pharmaceuticals?

Ionis Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of Ionis Pharmaceuticals?

To buy shares of DE:ISI, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Ionis Pharmaceuticals (ISI) Stock Forecast & Price Target

ISI Analyst Ratings

ISI Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ionis Pharmaceuticals

ISI Analyst Recommendation Trends

ISI Financial Forecast

ISI Earnings Forecast

ISI Sales Forecast

ISI Stock Forecast FAQ

Detailed List of Analyst Forecasts